A/APublished research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Cerebrospinal T-tau levels compared to the general population.
A/GPublished research associates this genotype (one copy of the reported risk allele) with an intermediate association with Cerebrospinal T-tau levels.
G/GPublished research associates this genotype with typical/baseline likelihood of Cerebrospinal T-tau levels — no copies of the reported risk allele.
rs769449 is a single position in the genome, in or near the APOE gene. Published research associates it with cerebrospinal t-tau levels. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
Does rs769449 affect how medicines work?
APOE carries pharmacogenomic findings for Lecanemab and other anti-amyloid antibodies. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.
Does having rs769449 mean I will get this?
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
Where does the information about rs769449 come from?
GWAS Catalog, Acta Neuropathol 2017, PMID:28247064. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.